SURPASS-2

Definition

The phase 3 head-to-head trial of tirzepatide versus semaglutide 1 mg (Ozempic dose) in adults with type 2 diabetes. Frías and colleagues (NEJM 2021) reported tirzepatide 15 mg achieving HbA1c reduction of -2.30 percentage points versus semaglutide -1.86 and body weight -11.2 kg versus -5.7 kg over 40 weeks. The first major head-to-head between the GLP-1 leaders.

SURPASS-2 trial deep-dive →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SUSTAIN-6
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Looking for more depth?

• SURPASS-2 trial deep-dive
• Browse the full GLP-1 glossary (124 terms across 8 categories)
• Research articles — primary-source deep dives
• Tools and calculators
• Compare GLP-1 telehealth providers